BLC
UTHR icon

Brown, Lisle/Cummings’s United Therapeutics UTHR Stock Holding History

Brown, Lisle/Cummings’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19K Buy
+2
New +$996 ﹤0.01% 914

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brown, Lisle/Cummings's UTHR Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in United Therapeutics (UTHR) in Q1 2026: 2 shares worth $1.19K. The stake represents ﹤0.01% of the portfolio and ranks #914 among its holdings.

853 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Brown, Lisle/Cummings held 2 shares of United Therapeutics worth $1.19K as of Q1 2026.
  • United Therapeutics was a new Brown, Lisle/Cummings position in Q1 2026.
  • United Therapeutics made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #914 holding.
  • 853 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.